Hot Biotech Stocks Recap: Nektar Therapeutics (NASDAQ:NKTR), Biostage, Inc. (NASDAQ:BSTG) – The Voice Registrar

Shares of Nektar Therapeutics (NASDAQ:NKTR) dropped -1.01% by the end of trading session at $14.64. For the current quarter, the 5 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.34/share, which would compare with -$0.14 in the year-ago quarter. The net percentage change is 27.97% over the last 12 months. The trading range in the same period had a highest hit of $19.98 while lowest level was $11.22. At the moment the price is 13.56% above its 50-day moving average and -1.11% below its 200-day moving average.

Nektar Therapeutics (NASDAQ:NKTR) on March 2, 2017 announced that its corporate presentation will be webcast at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. Eastern time. Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektars proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Biostage, Inc. (NASDAQ:BSTG) last exchanged hands at a price $0.39/share, registering a gain of 9.68%. Among 1 Wall Street analysts tracked by Thomson/First Call, the average PT for BSTG is $3 but some of them are predicting the price to move at the $3 level. If the most optimistic analysts are correct, the expected total return from the current price would be 669.23. The number of shares traded in most recent trading day was 3.06M shares which averages 987.24K shares a day. Its previous fifty two week high was $2.86 and moved down -75.47% over the same time frame, currently having a market cap around $13.09 million. Shares have risen -51.55% over the trailing six months. At the moment, the stock trades -43.63% below its 50-day moving average and -59.6% below its 200-day moving average.

Biostage, Inc. (NASDAQ:BSTG) ) on March 2, 2017 announced that it will report its financial results for the year ended December 31, 2016 in a press release that will be issued pre-market on Thursday, March 9, 2017. Biostage Management also announced that it will host a conference call with live audio webcast that same day at 9:00 a.m. ET to review its operational progress, expected near-term milestones and financial report. Biostage is a biotechnology company developing bioengineered organ implants based on the Companys new Cellframe technology which combines a proprietary biocompatible scaffold with a patients own stem cells to create Cellspan organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

The rest is here:
Hot Biotech Stocks Recap: Nektar Therapeutics (NASDAQ:NKTR), Biostage, Inc. (NASDAQ:BSTG) - The Voice Registrar